Stockscreener 앱 받기
0.505
2.43%
0.012
시장 영업 전:
.51
0.005
+0.99%
전일 마감가:
$0.493
열려 있는:
$0.5
하루 거래량:
429.03K
Relative Volume:
0.39
시가총액:
$29.30M
수익:
-
순이익/손실:
$-123.46M
주가수익비율:
-0.195
EPS:
-2.59
순현금흐름:
$-104.11M
1주 성능:
+1.00%
1개월 성능:
-27.05%
6개월 성능:
-70.29%
1년 성능:
-74.49%
1일 변동 폭
$0.493
$0.52
1주일 범위
$0.4515
$0.52
52주 변동 폭
$0.45
$4.02
바이오아틀라 Stock (BCAB) Company Profile
명칭
Bioatla Inc
전화
858-558-0708
주소
11085 TORREYANA ROAD, SAN DIEGO
BCAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.505 | 29.30M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
바이오아틀라 Stock (BCAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | 개시 | JMP Securities | Mkt Outperform |
| 2022-05-05 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-06-28 | 개시 | ROTH Capital | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | BTIG Research | Buy |
| 2021-01-11 | 개시 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | JP Morgan | Overweight |
| 2021-01-11 | 개시 | Jefferies | Buy |
모두보기
바이오아틀라 주식(BCAB)의 최신 뉴스
Jane Street Group LLC Decreases Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Stock Price Down 6.1% – Here’s Why - Defense World
Bioatla stock hits 52-week low at $0.57 amid sharp decline - Investing.com
Bioatla stock hits 52-week low at $0.57 amid sharp decline By Investing.com - Investing.com South Africa
BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
**BioAtla Updates Corporate Presentation in 8-K Filing** - Defense World
BioAtla Announces Registered Direct Offering to Advance Clinical Programs to Key Inflection PointsSan Diego, Calif., December 20, 2024 – BioAtla, Inc. (NASDAQ: BCAB), a global clinical-stage biotechnology company, disclosed on December 19, 2024, that - Defense World
Bioatla stock hits 52-week low at $1.02 amid market challenges - Investing.com Australia
BioAtla Secures $9.2M for Clinical Program Advancements - TipRanks
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points - The Manila Times
BioAtla Highlights Advancements in CAB Cancer Therapy - TipRanks
BioAtla announces $9.2 million stock and warrant sale - Investing.com
BioAtla announces $9.2 million stock and warrant sale By Investing.com - Investing.com Canada
BioAtla announces registered direct offering to advance two mid-stage clinical programs, shares fall - Seeking Alpha
BioAtla Secures $9.2M Funding Through Strategic Stock Offering to Advance Clinical Programs - StockTitan
Insiders Give Up US$66k As BioAtla Stock Drops To US$1.31 - Yahoo Finance
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting - The Manila Times
BioAtla's Lung Cancer Drug Shows Promising 58% One-Year Survival Rate in Key Clinical Data - StockTitan
BioAtla's SWOT analysis: oncology biotech stock faces pivotal year By Investing.com - Investing.com South Africa
BioAtla's SWOT analysis: oncology biotech stock faces pivotal year - Investing.com
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting - Quantisnow
BioAtla, Inc. (NASDAQ:BCAB) Q3 2024 Earnings Call Transcript - MSN
Michael Burry's Scion fund exits BioAtla, boosts Alibaba stake, adds puts: top Q3 trades - MSN
GSA Capital Partners LLP Purchases New Position in BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
BioAtla, Inc. (NASDAQ:BCAB) Sees Significant Drop in Short Interest - MarketBeat
HC Wainwright Weighs in on BioAtla FY2024 Earnings - Defense World
FY2024 Earnings Estimate for BioAtla Issued By HC Wainwright - MarketBeat
Analysis of TANG CAPITAL MANAGEMENT LLC's Recent Transaction in BioAtla Inc - GuruFocus.com
BioAtla (NASDAQ:BCAB) Rating Lowered to Neutral at HC Wainwright - Defense World
Michael Burry's Scion fund exits BioAtla, boosts Alibaba stake, adds puts: top Q3 trades (HPP:NYSE) - Seeking Alpha
HC Wainwright & Co. Downgrades BioAtla (BCAB) - MSN
BioAtla (NASDAQ:BCAB) Downgraded to "Neutral" Rating by HC Wainwright - MarketBeat
BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Head to Head Review: Alector (NASDAQ:ALEC) vs. BioAtla (NASDAQ:BCAB) - Defense World
3 Promising US Penny Stocks With At Least $90M Market Cap - Simply Wall St
BioAtla Reports Q3 2024 Financial Results and Clinical Advances - TipRanks
BioAtla reports Q3 EPS (22c), consensus (36c) - TipRanks
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress - StockTitan
BioAtla (BCAB) Scheduled to Post Earnings on Thursday - MarketBeat
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024 - The Manila Times
BioAtla, Inc. (NASDAQ:BCAB) has caught the attention of institutional investors who hold a sizeable 39% stake - Yahoo Finance UK
BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update - MarketBeat
바이오아틀라 (BCAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):